Description
Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 µM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness.
Product information
CAS Number: 1092977-61-1
Molecular Weight: 278.39
Formula: C16H26N2O2
Chemical Name: 2-{[2-(3-butoxyphenyl)ethyl]amino}-N,N-dimethylacetamide
Smiles: CCCCOC1=CC(CCNCC(=O)N(C)C)=CC=C1
InChiKey: GRHBODILPPXVKN-UHFFFAOYSA-N
InChi: InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : 290 mg/mL (1041.70 mM; Need ultrasonic).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
Evenamide selectively blocks voltage-gated sodium channels (VGSCs) in a voltage-and use-dependent manner (Ki=0.4 µM) and modulates sustained repetitive firing without inducing impairment of the normal neuronal excitability. Evenamide does not bind, inhibit or interact with over 130 receptors, enzymes, or transporters.
In Vivo:
Evenamide is active in a wide range of psychiatric animal models in monotherapy and addon to antipsychotics. Evenamide is effective in attenuating the social interaction deficit in Cl 395 (PCP)-impaired rats (MED=1 mg/kg po).
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.